The IFI44 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population disrupting the IFI44 gene in HeLa cells. This loss-of-function model enables investigation of IFI44??s roles in antiviral innate immunity, apoptosis, and mitochondrial dynamics. By eliminating IFI44 expression, these cells allow dissection of type I interferon signaling pathways. The polyclonal nature ensures genetic diversity, minimizing clonal artifacts while maintaining robust gene disruption.
The HeLa cell line, derived from human cervical adenocarcinoma, serves as a widely adopted epithelial cell model for studying cancer biology, signal transduction, and host-pathogen interactions. These cells exhibit a stable karyotype and are permissive to various viral infections, making them particularly suitable for examining interferon-mediated antiviral mechanisms. The epithelial origin of HeLa cells recapitulates key aspects of mucosal immunity, where type I interferon responses are critical. In the context of IFI44 knockout, the HeLa background allows exploration of innate immune signaling and apoptosis pathways in a cancer-relevant environment with intact JAK-STAT pathway components.
IFI44 operates downstream of type I interferons (IFN-??/??) via the JAK-STAT pathway. Interferon binding to IFNAR activates JAK1, which phosphorylates STAT1; together with IRF9, this induces ISGs including IFI44. IFI44 interacts with mitochondrial proteins such as mitofusin-2 (MFN2) and import complexes, regulating mitochondrial dynamics. It also modulates apoptosis through caspase-3/7 and BCL-2 family proteins, and sustains ISG expression by feedback on STAT1. Disruption of IFI44 therefore impairs ISG induction, destabilizes mitochondrial networks, and alters apoptotic thresholds.
In the HeLa cellular environment, IFI44 knockout offers a powerful tool to decouple type I interferon-driven antiviral responses from mitochondrial-mediated apoptosis and cell survival pathways. The loss of IFI44 function is particularly relevant for dissecting mechanisms underlying systemic lupus erythematosus, where dysregulated interferon signaling and elevated ISG expression are hallmarks, and for studying viral evasion strategies that target interferon-inducible effectors. Researchers can employ this model to examine how IFI44 deficiency impacts cell viability, mitochondrial morphology, and innate immune signaling in cervical cancer cells, providing insights into the intersection of oncology and immunology.
Applications include viral infection assays to compare antiviral responses between wild-type and knockout HeLa cells, and RNA-seq-based transcriptomic profiling for ISG expression analysis. Western blotting of IFI44 and cleaved caspases, along with Annexin V flow cytometry, assesses apoptosis. Immunofluorescence for MFN2 reveals mitochondrial morphology changes, and RT-qPCR validates impaired interferon signaling. These polyclonal cells are also suitable for drug screening in interferonopathies. For further information, contact Ascent Research.
